Esperion Therapeutics (ESPR) Non Operating Income (2012 - 2026)

Esperion Therapeutics has reported Non Operating Income for 15 years, with the latest figure at $1.2 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income rose 10.35% year-over-year to $1.2 million; the trailing twelve-month figure through Mar 2026 stood at $3.6 million (down 43.0% YoY), and the FY2025 full-year result was $3.5 million, down 56.49% from the prior year.
• Non Operating Income for Q1 2026 stood at $1.2 million, up from $1.1 million in the prior quarter.
• The five-year high for Non Operating Income was $2.8 million in Q1 2024, with the low at $318000.0 in Q2 2022.
• Historically, Non Operating Income has averaged $1.2 million across 5 years, with a median of $1.2 million in 2026.
• Annual changes were most pronounced in 2022 — Non Operating Income surged 4969.23% — and 2025, when it tumbled 72.86%.
• Esperion Therapeutics' Non Operating Income stood at $1.4 million in 2022, then declined by 20.3% to $1.1 million in 2023, then rose by 11.76% to $1.2 million in 2024, then retreated by 10.94% to $1.1 million in 2025, then advanced by 10.05% to $1.2 million in 2026.
• The last three Non Operating Income figures came in at $1.2 million (Q1 2026), $1.1 million (Q4 2025), and $677000.0 (Q3 2025), per Business Quant data.